Zentalis Pharmaceuticals Inc

ZNTL

Equity

ISIN US98943L1070 / Valor 53183848

NASDAQ (2024-09-18)

USD 4.16+1.46%

Zentalis Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in discovering and developing small molecule therapeutics for the treatment of various cancers. The company's focus is on targeting fundamental biological pathways of cancer to develop clinically differentiated treatments. With a strong emphasis on research and development, Zentalis Pharmaceuticals Inc aims to bring innovative therapies to market to improve outcomes for cancer patients.

Summarized from source with an LLMView SourceSector: Technology

License Revenue

Zentalis Pharmaceuticals Inc. reported license revenue of $40.56 million for the first quarter of 2024, compared to no license revenue in the same quarter of 2023. This significant increase highlights the company's successful licensing agreements and partnerships.

Operating Expenses

For the first quarter of 2024, Zentalis Pharmaceuticals Inc. incurred total operating expenses of $65.33 million, slightly up from $64.95 million in the first quarter of 2023. The expenses were primarily driven by research and development costs, which totaled $49.59 million.

Net Income

Zentalis Pharmaceuticals Inc. achieved a net income of $10.04 million in the first quarter of 2024, a substantial improvement from a net loss of $63.26 million in the same period of 2023. This turnaround was supported by increased license revenue and investment income.

Earnings Per Share

In the first quarter of 2024, Zentalis Pharmaceuticals Inc. reported basic and diluted earnings per share of $0.14, compared to a loss per share of $1.07 in the first quarter of 2023. This positive earnings per share reflects the company's improved financial performance.

Cash and Equivalents

As of March 31, 2024, Zentalis Pharmaceuticals Inc. had cash, cash equivalents, and marketable securities totaling $488.98 million, up from $482.92 million as of December 31, 2023. This increase in cash reserves provides the company with a strong financial position to support its ongoing operations and development activities.

Summarized from source with an LLMView Source

Key figures

-81.5%1Y

-94.1%3Y

%5Y

Performance

111%1Y

88.8%3Y

83.9%5Y

Volatility